Cardiovascular Toxic Effects of Targeted Cancer Therapies.
about
Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits.Tyrosine kinase-targeting drugs-associated heart failure.Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity.The Role of Biomarkers in Detection of Cardio-toxicity.Cardiovascular Complications Associated With Novel Cancer Immunotherapies.Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant.Cardiovascular Risk in Survivors of Cancer.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.Incidence of cancers in patients with atherosclerotic cardiovascular diseasesCardiotoxicity of cancer chemotherapy: identification, prevention and treatment.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer.Best Practices in Counseling Young Female Cancer Survivors on Reproductive Health.Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.Caution needed in introduction of provisional approvals for medicines.Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience.Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Association of atrial fibrillation and cancer: Analysis from two large population-based case-control studies.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.Cardiotoxicity of Anticancer Therapeutics.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.Lung cancer as a cardiotoxic state: a review.Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.Cardiotoxicity of immune checkpoint inhibitors.Grounding Cardio-Oncology in Basic and Clinical Science.Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with LightCardiotoxicity: precision medicine with imprecise definitionsCardio-oncology: A Focus on Cardiotoxicity
P2860
Q33675082-5F8CEC49-3CA4-4B3F-A005-417C2038C538Q38401605-8214FC02-E9F8-46A5-92C0-DF5D5728570FQ38632789-E3F090EF-0BE2-45AE-B98E-056C4246FACCQ38728535-FB9FCE54-0E8E-46EC-96C0-7BB174626F65Q38731522-40F92A65-6468-4959-B381-E49D4FA0FCC8Q38735433-B24180C2-996B-494E-8A16-157A8F93B60CQ39078275-F4F6D767-1D5B-47C8-8526-12A9F142E04DQ39270177-6774BCF1-A0E2-4685-A84D-2D23C0D5820FQ39333736-31ED30DF-4E07-4239-A87F-B213105CC59FQ39344380-C6B0CC77-5848-4C16-8B32-6159CC3FA358Q39384416-3C5EA3EB-6DB3-4A0B-B083-22E592082781Q41692410-AF92AA7E-F132-4142-870D-6C3BD5FED262Q41704131-C037BF25-CED0-406C-9D33-B4921D307996Q45073135-669B37CB-84B9-487F-A6D3-501D4E17CA96Q45073137-DECB1EB1-6EF0-47B3-8FDA-C98C623AB8DDQ45374763-BE12433A-DE37-4FC7-83EE-9AE38FBB5A7BQ46065513-1367C58A-28AE-4635-8079-770F8E3F5F0DQ47283034-213CDFFA-7F18-455E-B40D-6AF530577381Q47565837-CAE8C77C-103A-4F2A-86D4-1200713B38F9Q47576767-17FEC5BE-2BC5-42EE-9D11-A3D899536F5FQ47630528-806E502A-79E3-41CD-BE06-44804B79A9ADQ47681122-4B5E5EB3-BCDC-4DF5-87E2-BC3774422C64Q48260065-DD22A462-0797-4239-B495-BF3B0F6E952BQ49315568-3D9FF3BA-05E5-45A5-92C6-77607C9DD587Q49568718-B2BF272F-3507-4705-9CAE-EB0375F62150Q49997360-8BA38BFF-E131-4F02-8013-17F97E214794Q50121120-3F6C6477-C19A-440B-8666-3BB3F25B8A4BQ50146298-0BD579D9-649B-4EF3-A940-1AF4CD46611AQ50326869-076C2340-4E50-4F6F-AB6F-E578BFFEA878Q52641875-9F53CEF5-0637-4BF0-8E52-BF8B0A45CAB7Q52723478-43128CAA-3B7B-4091-974F-2CFE1A9C9BD7Q53117997-10ECB814-4A8D-4D9C-B906-F4F81499DAB8Q54976923-03A760FD-4196-45CE-A36D-37138D276774Q55075057-A14C5133-E346-40CE-8A52-EFB3D46C1393Q55339567-B8AD9145-D7B6-4D8D-AD0A-5901CD0CA7BEQ55438414-1E181185-AB47-46C2-B4BE-63D0540CDC3DQ55510616-2A2D0682-83EF-4FE4-8377-6622B3531EB8Q57027739-B137C9D7-259F-4183-A743-DE7C53AEF349Q57252863-7D1AFF11-6999-4B05-84F2-1A13F8E6EA13Q57495835-2E2270C9-51BC-4CEF-B27C-593BB2DB5582
P2860
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
@en
type
label
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
@en
prefLabel
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
@en
P356
P1476
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
@en
P2093
Javid J Moslehi
P304
P356
10.1056/NEJMRA1100265
P407
P577
2016-10-01T00:00:00Z